SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Big Sponsors > Johnson & Johnson

CRO Evotec sees spin-out firm as strategic opportunity

12-May-2016 - Evotec’s auto-immune spin-out Topas represents “a strategic opportunity” for the CRO, which reported strong first quarter sales this week.

Novartis joint venture helps virtual trial CRO to $6.5m fundraising round

26-Oct-2015 - Science 37 has raised $6.5m (€5.7m) from Lux Capital and dRx Capital, the fund set up by Novartis and Qualcomm, to advance its virtual clinical trial service business.

Bavarian Nordic wins up to $33m to develop J&J Ebola vaccine

16-Sep-2015 - Danish biotech Bavarian Nordic has signed a $9m contract from Johnson & Johnson to improve stability of their joint Ebola vaccine. After options and milestone awards, payment could total $33m.

Research consortium looks to identify biomarkers for autism treatments

21-Jul-2015 - A new four-year research project involving a consortium of government, non-profit and other large biopharma partners is aiming to create a set of measures that can be used in clinical...

Exporting to Brazil? ANVISA is tough and hands-on, says Kemwell

10-Jun-2015 - Site audits by Brazilian pharma regulator ANVISA are “exactly the opposite” to the US FDA’s, says CMO Kemwell as it prepares to export to Brazil for Johnson & Johnson.

Antiquated clinical trial industry ripe for change from innovation, experts say

15-May-2015 - Experts across the sponsor-CRO spectrum seem to agree on at least one thing: the clinical trial process is ready for a major transformation, though how quickly and what types of...

Bio-CMO sector to grow over 40% on Big Biopharma's burgeoning pipelines

24-Apr-2015 - Cheaper disposable manufacturing techs and increased demand for outsourced production will see more CMOs enter the contracting sector according to HighTech Business Decisions

News in brief

$100m Big Pharma-backed VC fund to focus on dementia research

17-Mar-2015 - Biogen Idec, GlaxoSmithKline, Johnson & Johnson, Lilly and Pfizer have all committed to investing in the $100m venture capital fund, alongside Alzheimer’s Research UK and the UK government.

Exclusive interview

Preclinical prices improving says Huntingdon CEO; firm is mulling US capacity expansion

05-Mar-2015 - Higher capacity utilization is improving prices across the non-clinical research sector according to Huntingdon Life Sciences CEO Brian Cass, who told Outsourcing-pharma.com the preclinical CRO may add scale to US...

HCV drugs Sovaldi and Olysio boost Q1 sales for AmeriSourceBergen

29-Jan-2015 - New hepatitis C drugs produced by Gilead, Janssen and AbbVie contributed to a first quarter spike in revenue for AmeriSourceBergen’s Pharmaceutical Distribution business.

PPD’s X-Chem signs multi-target collaboration with Janssen

12-Jan-2015 - PPD’s recently acquired biotech company X-Chem is launching a multi-target collaboration with Janssen Biotech. Financial terms of the deal were not disclosed.  

European CRO Evotec cashes in on strategic partnerships

23-Dec-2014 - Contract drug developer Evotec AG has achieved multiple milestones resulting in €8m ($9.8m) in revenue thanks to its collaborations with Bayer and Janssen Pharmaceuticals.

Janssen updates manufacturing software systems at Belgium API plant

15-Dec-2014 - Johnson & Johnson has updated its manufacturing execution software (MES) at an active pharmaceutical ingredient (API) in Belgium.

CMO use to grow despite Big Biopharma's in-house spend, say experts

02-Dec-2014 - Third-party manufacturers anxious about Big Biopharma investments and downbeat industry reports can relax as experts concur “it’s a time of growth for biopharmaceutical outsourcing.”

Dispatches from AAPS 2014

BARDA: Ebola is “a bioterrorism threat”

06-Nov-2014 - BARDA, the US government’s Biomedical Advanced Research and Development Authority, has revealed it sees Ebola “as a bioterrorism threat.”

Mercks & recreation? The pharma industry and the sporting world

03-Nov-2014 - In an Outsourcing-Pharma sporting special, we reveal why GSK will not be at the Rio Olympics, why PPD has renewed its ironman triathlon sponsorship, and what became of BMS' partnership with Lance...

GSK: GM yeast breakthrough won't kill off poppy-based opium

28-Aug-2014 - Poppies will continue to be the main source of industrial opiates long-term according to GSK, despite a recent breakthrough in efforts to produce it in GM yeast.

Ben Venue assets will bolster sterile injectables network, says Hikma

28-Jul-2014 - Hikma has bought defunct manufacturer Ben Venue and says it could reactivate the site in the long-term, despite the transfer of equipment across its sterile injectables network.

Janssen's tramadol supply chain ready for DEA's rescheduling deadline

16-Jul-2014 - Janssen Pharmaceuticals is prepared for Tramadol's reclassification by the US Drug Enforcement Administration (DEA) and says the supply of its versions of the opioid analgesic will not be interrupted.

J&J's energy answers are blowing in the wind in Irish collaboration

09-Jun-2014 - J&J says it collaborated with Novartis and GSK to install wind turbines in Cork, Ireland to substantially reduce electricity costs at its local manufacturing plants.

Australia risks losing leading pharma opium supplier status

13-Mar-2014 - Australia may lose its status as the leading supplier of pharma grade opium if it does not comply with Big Pharma requests and allow cultivation of the crop on the...

People - Mylan to maximise opportunities with new EU President

21-Oct-2013 - News from Mylan in Europe and Johnson & Johnson tops this week's in-Pharmatechnologist.com's People on the Move.

Boehringer CMO Ben Venue Labs to close permanently, layoff 1,100

04-Oct-2013 - Beleaguered sterile injectables manufacturer Ben Venue Laboratories has announced it will close permanently by the end of 2013 and lay off 1,100 employees in Ohio.

Mold, API contaminants prompt more J&J recalls

16-Sep-2013 - Johnson & Johnson is battling another onset of quality concerns as its subsidiary Janssen is pulling one lot of its Risperdal Consta injection in the US due to a mold...

People: New Chairman for J&J's China Divisions

02-Sep-2013 - Johnson & Johnson has reorganised its Chinese divisions under one Chairman, and Merck KGaA has a new CIO - welcome to in-Pharmatechnologist's People on the Move.

Key Industry Events